MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
BioLife Solutions Revenue 2011-2026 | BLFS
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue BioLife Solutions
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 82.3 M | 75.9 M | 76.2 M | 119 M | 48.1 M | 27.4 M | 19.7 M | 11 M | 8.23 M | 6.19 B | 6.19 M | 8.95 M | 5.66 M | 2.76 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.19 B | 2.76 M | 477 M |
Quarterly Revenue BioLife Solutions
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28.1 M | 25.4 M | 23.9 M | - | 21.4 M | 19.7 M | 18.4 M | - | 23.6 M | 29.2 M | 37.7 M | - | 40.7 M | 40.5 M | 36.2 M | - | 33.8 M | 31.2 M | 16.8 M | - | 11.3 M | 9.92 M | 12.2 M | - | -291 K | -217 K | -232 K | - | -43 K | -177 K | -144 K | - | -218 K | -260 K | -229 K | - | - | - | - | - | 4.73 K | 5.48 K | 8.24 K | - | 7.66 K | 4.52 K | - | - | - | - | 2.16 M | - | 1.68 M | 1.1 M | 836 K | - | 716 K | 623 K | 611 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 40.7 M | -291 K | 12 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical instruments industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
169 M | - | - | $ 810 M |  USA |
 |
Baxter International
BAX
|
2.75 B | $ 21.07 | 1.81 % | $ 10.7 B | USA |
 |
Becton, Dickinson and Company
BDX
|
21.8 B | $ 202.8 | -1.16 % | $ 58.3 B | USA |
 |
Luminex Corporation
LMNX
|
417 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
1.58 M | - | -9.52 % | $ 20.6 M | USA |
 |
ICU Medical
ICUI
|
2.38 B | $ 151.86 | 0.14 % | $ 3.7 B | USA |
 |
iRhythm Technologies
IRTC
|
592 M | $ 180.4 | -4.68 % | $ 5.63 B | USA |
 |
Repro Med Systems
KRMD
|
28.5 M | $ 5.67 | -2.41 % | $ 259 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
150 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
1.02 B | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
106 M | - | - | $ 282 M | USA |
 |
Masimo Corporation
MASI
|
2.09 B | $ 140.04 | 1.54 % | $ 7.46 B | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
2.88 B | - | -0.05 % | $ 10.3 B | USA |
 |
Merit Medical Systems
MMSI
|
1.36 B | $ 86.37 | -7.31 % | $ 5.03 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
17.9 M | $ 8.03 | -1.95 % | $ 162 M | USA |
 |
Varian Medical Systems, Inc.
VAR
|
3.17 B | - | -0.02 % | $ 16.3 B | USA |
 |
Alcon
ALC
|
9.91 B | $ 80.27 | -0.43 % | $ 40.4 B |  Schweiz |
 |
Predictive Oncology
POAI
|
1.62 M | $ 6.83 | 1.08 % | $ 37.2 M | USA |
 |
AtriCure
ATRC
|
465 M | $ 41.66 | -1.76 % | $ 1.96 B | USA |
 |
electroCore
ECOR
|
16 M | $ 5.62 | 11.73 % | $ 31 K | USA |
 |
Haemonetics Corporation
HAE
|
1.36 B | $ 82.2 | -2.19 % | $ 4.14 B | USA |
 |
AngioDynamics
ANGO
|
292 M | $ 9.97 | -0.8 % | $ 407 M | USA |
 |
Harvard Bioscience
HBIO
|
112 M | $ 0.64 | -1.79 % | $ 27.1 M | USA |
 |
The Cooper Companies
COO
|
4.09 B | $ 83.71 | 0.69 % | $ 16.7 B | USA |
 |
LeMaitre Vascular
LMAT
|
220 M | $ 84.83 | -0.25 % | $ 1.9 B | USA |
 |
Glaukos Corporation
GKOS
|
315 M | $ 113.09 | -0.93 % | $ 5.48 B | USA |
 |
InfuSystem Holdings
INFU
|
110 M | $ 8.61 | -4.01 % | $ 178 M | USA |
 |
Isoray
ISR
|
3.55 M | - | 0.03 % | $ 108 M | USA |
 |
Nephros
NEPH
|
14.2 M | $ 4.89 | -2.5 % | $ 50.8 M | USA |
 |
Utah Medical Products
UTMD
|
12.3 M | $ 59.83 | 1.87 % | $ 217 M | USA |
 |
Intuitive Surgical
ISRG
|
8.35 B | $ 587.18 | 0.36 % | $ 209 B | USA |
 |
Microbot Medical
MBOT
|
117 K | $ 2.08 | -5.02 % | $ 21.2 M |  Israel |
 |
Milestone Scientific
MLSS
|
8.63 M | $ 0.3 | 1.23 % | $ 23.9 M | USA |
 |
NeuroMetrix
NURO
|
3.03 M | - | 5.05 % | $ 9.02 M | USA |
 |
Envista Holdings Corporation
NVST
|
2.51 B | $ 23.57 | -0.23 % | $ 4.06 B | USA |
 |
OraSure Technologies
OSUR
|
186 M | $ 2.63 | -1.13 % | $ 196 M | USA |
 |
Pro-Dex
PDEX
|
66.6 M | $ 41.51 | 0.51 % | $ 136 M | USA |
 |
Pulse Biosciences
PLSE
|
700 K | $ 14.63 | -0.61 % | $ 703 M | USA |
 |
Repligen Corporation
RGEN
|
632 M | $ 166.85 | 0.26 % | $ 9.3 M | USA |
 |
ResMed
RMD
|
3.58 B | $ 252.15 | 0.49 % | $ 36.8 B | USA |
 |
STERIS plc
STE
|
5.46 B | $ 258.0 | -1.03 % | $ 25.4 B | USA |
 |
Stereotaxis
STXS
|
26.8 M | $ 2.53 | -2.13 % | $ 204 M | USA |
 |
Retractable Technologies
RVP
|
33 M | $ 0.76 | -2.53 % | $ 22.8 M | USA |
 |
STAAR Surgical Company
STAA
|
314 M | $ 22.06 | -1.96 % | $ 1.08 B | USA |
 |
Teleflex Incorporated
TFX
|
3.05 B | $ 112.75 | 2.49 % | $ 5.28 B | USA |
 |
West Pharmaceutical Services
WST
|
2.89 B | $ 275.51 | 0.1 % | $ 20.1 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
3.79 B | $ 12.76 | 2.2 % | $ 2.59 B | USA |